Drug Trial News

RSS

High-dose flu vaccine protects older adults with lung disease

The risk of being hospitalized for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined results of two large clinical trials presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

8 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Oral drug offers promising advance for children with achondroplasia

A phase 3 trial is showing "a potentially giant step forward," in treating children with achondroplasia, UCLA Health's Dr. Isidro B. Salusky wrote in a new editorial published in the New England Journal of Medicine (NEJM).

4 Sep 2026

Prednisone may impair bone health in children with Duchenne muscular dystrophy

In a new study published in Scientific Reports, an international and multidisciplinary research team including Binghamton University researchers identified a set of blood proteins that may explain why the corticosteroid prednisone, although beneficial in treating Duchenne muscular dystrophy (DMD), can interfere with childhood growth and bone health.

4 Sep 2026

More major insurance companies covering Kerecis intact fish-skin grafts as new studies show big benefits for burns and diabetic foot ulcers

Kerecis, the company pioneering the use of sustainably sourced fish‑skin grafts in cellular therapy and tissue regeneration, has significantly expanded U.S. insurance coverage, adding more than 40 million covered lives through recent policy updates across multiple large national and regional insurers, as well as state Medicaid programs.

3 Sep 2026

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

Antiviral COVID-19 drug shows no benefit for Long COVID

Results from a clinical trial funded by the National Institutes of Health (NIH) and published today in the journal Lancet Infectious Diseases show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.

1 Sep 2026

Laser-based therapy shows promise against dangerous abdominal infections in children

Children whose appendix has burst often develop serious abdominal infections that are hard to treat and increasingly resistant to antibiotics.

1 Sep 2026

Protein build-up may shape cancer drug response

The way cancer-causing proteins accumulate in tumors may influence how effectively a promising new generation of medicines can remove them, a study suggests.

31 Aug 2026

SHASTA trials show substantial triglyceride reductions with plozasiran

Plozasiran significantly reduced triglyceride levels in severe hypertriglyceridemia patients, showing promise in preventing acute pancreatitis after one year.

31 Aug 2026

Oral relaxin agonist AZD5462 improves cardiac function in heart failure patients

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in Circulation.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026

H-ISDN shows no significant benefit in broader heart failure population

In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.

30 Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.

29 Aug 2026

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

29 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026